Kopran Limited
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides d… Read more
Kopran Limited (KOPRAN) - Net Assets
Latest net assets as of September 2025: ₹5.01 Billion INR
Based on the latest financial reports, Kopran Limited (KOPRAN) has net assets worth ₹5.01 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹8.13 Billion) and total liabilities (₹3.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹5.01 Billion |
| % of Total Assets | 61.62% |
| Annual Growth Rate | 5.64% |
| 5-Year Change | 111.54% |
| 10-Year Change | 376.79% |
| Growth Volatility | 26.86 |
Kopran Limited - Net Assets Trend (2004–2025)
This chart illustrates how Kopran Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kopran Limited (2004–2025)
The table below shows the annual net assets of Kopran Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹5.18 Billion | +5.52% |
| 2024-03-31 | ₹4.91 Billion | +11.84% |
| 2023-03-31 | ₹4.39 Billion | +3.07% |
| 2022-03-31 | ₹4.26 Billion | +73.92% |
| 2021-03-31 | ₹2.45 Billion | +29.18% |
| 2020-03-31 | ₹1.90 Billion | +12.59% |
| 2019-03-31 | ₹1.68 Billion | +16.42% |
| 2018-03-31 | ₹1.45 Billion | +8.42% |
| 2017-03-31 | ₹1.33 Billion | +22.77% |
| 2016-03-31 | ₹1.09 Billion | +10.35% |
| 2015-03-31 | ₹985.19 Million | -14.00% |
| 2014-03-31 | ₹1.15 Billion | +17.84% |
| 2013-03-31 | ₹972.17 Million | +13.01% |
| 2012-03-31 | ₹860.23 Million | +6.91% |
| 2011-03-31 | ₹804.64 Million | +8.01% |
| 2010-03-31 | ₹744.96 Million | +13.88% |
| 2009-03-31 | ₹654.18 Million | -8.05% |
| 2008-03-31 | ₹711.43 Million | +46.24% |
| 2007-03-31 | ₹486.48 Million | -46.23% |
| 2006-03-31 | ₹904.79 Million | +29.80% |
| 2005-03-31 | ₹697.08 Million | -57.42% |
| 2004-03-31 | ₹1.64 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kopran Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 224540700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹1.82 Billion | 35.19% |
| Common Stock | ₹482.86 Million | 9.32% |
| Other Comprehensive Income | ₹419.63 Million | 8.10% |
| Other Components | ₹2.46 Billion | 47.40% |
| Total Equity | ₹5.18 Billion | 100.00% |
Kopran Limited Competitors by Market Cap
The table below lists competitors of Kopran Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
InspireMD Inc
NASDAQ:NSPR
|
$34.20 Million |
|
IMMUCELL CORP. DL-10
F:IUL
|
$34.21 Million |
|
SVB & T Corp
OTCQX:SVBT
|
$34.21 Million |
|
Hancock & Gore Ltd
AU:HNG
|
$34.22 Million |
|
IX Acquisition Corp
NASDAQ:IXAQ
|
$34.18 Million |
|
Kyongbo Pharmaceutical Co Ltd
KO:214390
|
$34.18 Million |
|
Tobii AB (publ)
F:24T
|
$34.18 Million |
|
Tristar Gold
OTCQB:TSGZF
|
$34.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kopran Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,912,450,000 to 5,183,479,000, a change of 271,029,000 (5.5%).
- Net income of 385,519,000 contributed positively to equity growth.
- Dividend payments of 144,632,000 reduced retained earnings.
- Share repurchases of 13,425,000 reduced equity.
- New share issuances of 13,425,000 increased equity.
- Other comprehensive income increased equity by 90,970,000.
- Other factors decreased equity by 60,828,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹385.52 Million | +7.44% |
| Dividends Paid | ₹144.63 Million | -2.79% |
| Share Repurchases | ₹13.43 Million | -0.26% |
| Share Issuances | ₹13.43 Million | +0.26% |
| Other Comprehensive Income | ₹90.97 Million | +1.75% |
| Other Changes | ₹-60.83 Million | -1.17% |
| Total Change | ₹- | 5.52% |
Book Value vs Market Value Analysis
This analysis compares Kopran Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.60x to 1.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | ₹76.33 | ₹122.01 | x |
| 2005-03-31 | ₹31.99 | ₹122.01 | x |
| 2006-03-31 | ₹34.24 | ₹122.01 | x |
| 2007-03-31 | ₹11.25 | ₹122.01 | x |
| 2008-03-31 | ₹20.18 | ₹122.01 | x |
| 2009-03-31 | ₹18.56 | ₹122.01 | x |
| 2010-03-31 | ₹20.57 | ₹122.01 | x |
| 2011-03-31 | ₹20.98 | ₹122.01 | x |
| 2012-03-31 | ₹22.03 | ₹122.01 | x |
| 2013-03-31 | ₹24.89 | ₹122.01 | x |
| 2014-03-31 | ₹29.33 | ₹122.01 | x |
| 2015-03-31 | ₹24.78 | ₹122.01 | x |
| 2016-03-31 | ₹26.26 | ₹122.01 | x |
| 2017-03-31 | ₹30.86 | ₹122.01 | x |
| 2018-03-31 | ₹33.46 | ₹122.01 | x |
| 2019-03-31 | ₹38.95 | ₹122.01 | x |
| 2020-03-31 | ₹43.85 | ₹122.01 | x |
| 2021-03-31 | ₹56.65 | ₹122.01 | x |
| 2022-03-31 | ₹96.18 | ₹122.01 | x |
| 2023-03-31 | ₹91.11 | ₹122.01 | x |
| 2024-03-31 | ₹101.89 | ₹122.01 | x |
| 2025-03-31 | ₹107.43 | ₹122.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kopran Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.44%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.12%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.63x
- Recent ROE (7.44%) is above the historical average (1.88%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -5.72% | -6.18% | 0.32x | 2.91x | ₹-257.38 Million |
| 2005 | -61.00% | -35.82% | 0.28x | 6.07x | ₹-494.96 Million |
| 2006 | -10.69% | -6.19% | 0.36x | 4.79x | ₹-187.23 Million |
| 2008 | -31.44% | -17.24% | 0.48x | 3.79x | ₹-294.82 Million |
| 2009 | 21.08% | 11.62% | 0.50x | 3.61x | ₹72.47 Million |
| 2010 | 0.64% | 0.29% | 0.70x | 3.15x | ₹-69.74 Million |
| 2011 | 6.04% | 2.50% | 0.84x | 2.89x | ₹-31.86 Million |
| 2012 | 6.21% | 2.68% | 0.79x | 2.91x | ₹-32.62 Million |
| 2013 | 11.44% | 4.44% | 0.95x | 2.71x | ₹13.97 Million |
| 2014 | 15.00% | 5.67% | 1.01x | 2.61x | ₹57.23 Million |
| 2015 | -39.71% | -12.01% | 1.18x | 2.79x | ₹-489.76 Million |
| 2016 | 9.86% | 3.62% | 1.12x | 2.43x | ₹-1.53 Million |
| 2017 | 14.92% | 6.43% | 1.04x | 2.24x | ₹65.65 Million |
| 2018 | 14.16% | 6.72% | 0.97x | 2.18x | ₹60.15 Million |
| 2019 | 14.26% | 6.89% | 0.99x | 2.09x | ₹71.75 Million |
| 2020 | 11.08% | 6.00% | 0.94x | 1.96x | ₹20.52 Million |
| 2021 | 25.14% | 12.80% | 1.10x | 1.79x | ₹371.03 Million |
| 2022 | 14.32% | 12.87% | 0.78x | 1.43x | ₹184.14 Million |
| 2023 | 6.20% | 4.97% | 0.84x | 1.48x | ₹-166.92 Million |
| 2024 | 10.37% | 8.29% | 0.83x | 1.51x | ₹18.32 Million |
| 2025 | 7.44% | 6.12% | 0.75x | 1.63x | ₹-132.83 Million |
Industry Comparison
This section compares Kopran Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $6,434,771,306
- Average return on equity (ROE) among peers: 24.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kopran Limited (KOPRAN) | ₹5.01 Billion | -5.72% | 0.62x | $34.19 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $16.96 Billion | 22.18% | 0.80x | $1.19 Billion |
| Marksans Pharma Limited (MARKSANS) | $9.05 Billion | 26.35% | 0.36x | $428.52 Million |
| NGL Fine-Chem Limited (NGLFINE) | $160.59 Million | 15.04% | 1.05x | $39.88 Million |
| Pfizer Limited (PFIZER) | $9.01 Billion | 33.25% | 0.22x | $818.67 Million |
| Sanofi India Limited (SANOFI) | $17.36 Billion | 17.53% | 0.46x | $376.73 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $324.08 Million |
| SENORES PHARMACEUTICALS L (SENORES) | $94.96 Million | 7.21% | 0.53x | $157.65 Million |
| SMS Pharmaceuticals Limited (SMSPHARMA) | $2.22 Billion | 9.19% | 1.30x | $105.56 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $982.22 Million | 14.46% | 1.13x | $31.85 Million |